Loading...
Market
Story
Amgen's Imdelltra for Advanced Lung Cancer Wins Accelerated US Approval
May 16, 2024, 07:09 PM
Amgen has received US FDA accelerated approval for its new drug, Imdelltra, designed to treat adult patients with advanced small cell lung cancer. The approval, granted on May 16, 2024, marks a significant step in the fight against this particularly aggressive form of cancer. The drug, also known as tarlatamab, is a targeted immunotherapy aimed at patients whose condition has worsened despite chemotherapy.
View original story
Similar markets
Revenue from Imdelltra exceeds $1 billion • 25%
Revenue from Imdelltra is $500 million to $1 billion • 25%
Revenue from Imdelltra is $100 million to $500 million • 25%
Revenue from Imdelltra is less than $100 million • 25%
Significant increase • 25%
Moderate increase • 25%
No significant impact • 25%
Decrease due to other factors • 25%
EU only • 25%
UK only • 25%
Japan only • 25%
Multiple regions including EU, UK, and Japan • 25%
Stock price increases by over 20% • 33%
Stock price increases by 10-20% • 33%
Stock price increases by less than 10% • 34%
Top performer • 33%
Average performer • 34%
Underperformer • 33%
Approved in EU • 25%
Approved in Asia • 25%
Approved in LATAM • 25%
Not approved in other regions • 25%